CagriSema
CagriSema is an investigational fixed-dose combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide, studied for weight reduction; research protocols typically use 2 mg weekly subcutaneously (titrating toward 6 mg).
Best for
It has been studied for body-weight reduction in adults with overweight or obesity, including those with type 2 diabetes, leveraging dual amylin- and GLP-1-pathway appetite suppression.
What to expect
Research reports gradual, progressive weight reduction over the course of treatment, with trial endpoints assessed at 68 weeks rather than an immediate effect.
Pairs with
As a fixed combination it already pairs an amylin analogue (cagrilintide) with a GLP-1 receptor agonist (semaglutide), and in research contexts it is studied alongside lifestyle and dietary intervention rather than stacked with additional agents.
In Phase 3 research it was administered as a once-weekly subcutaneous injection of a fixed-dose combination (cagrilintide 2.4 mg plus semaglutide 2.4 mg), typically reached through gradual dose titration over several weeks.
- How often
- Weekly
- When
- Morning
- Route
- Subcutaneous
- Vial & water
- 10 mg vial in 1 mL = 10 mg/mL · 2 mg = 20 units on a U-100 syringe
- Cycle
- Start 2 mg weekly, titrate within 2–6 mg as tolerated
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
No approved brand anywhere. This combination is still under review, and "CagriSema" is the developer’s programme name rather than a marketed brand — the name it launches under may differ.
CagriSema is an investigational fixed-dose combination of two peptide analogues: cagrilintide, a long-acting amylin analogue (characterized as a dual amylin and calcitonin receptor agonist), and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
CagriSema is not FDA-approved; Novo Nordisk submitted a New Drug Application in December 2025, and as of this writing it remains an investigational combination under regulatory review.
The two components are designed to act on distinct but complementary appetite-regulating pathways — cagrilintide engages amylin/calcitonin receptors in brainstem and hypothalamic circuits to promote satiety and slow gastric emptying, while semaglutide acts on GLP-1 receptors to reduce appetite, slow gastric emptying, and modulate glucose-dependent insulin and glucagon secretion. Research, including the Phase 3 REDEFINE 1 and REDEFINE 2 trials published in 2025, has characterized once-weekly subcutaneous CagriSema (cagrilintide 2.4 mg / semaglutide 2.4 mg) for body-weight reduction in adults with overweight or obesity, with and without type 2 diabetes.
- Half-life
- ~1 week for both components (semaglutide ~7 d, cagrilintide ~7-8 d)
- Peak
- ~1-3 days post-SC; steady state ~4-5 weeks
- Absorption
- Slow SC depot absorption; albumin-binding acylation enables once-weekly dosing
- Bioavailability
- Semaglutide SC ~89%; cagrilintide high SC (combo value not separately published)
References2
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.